Business Wire

Swissmedic Approves Carbetocin Ferring for the Prevention of Postpartum Haemorrhagein All Births


Ferring Pharmaceuticals today welcomes the Swissmedic approval of Carbetocin Ferring, a heat-stable formulation of carbetocin, for the prevention of excessive bleeding after childbirth following all births, both vaginal and caesarean section.5

This press release features multimedia. View the full release here:

Nigeria: Anita suffered from postpartum haemorrhage after the birth of her first child, and needed a blood transfusion to save her life. (Photo: Business Wire)

Nigeria: Anita suffered from postpartum haemorrhage after the birth of her first child, and needed a blood transfusion to save her life. (Photo: Business Wire)

Every year, 14 million women experience excessive bleeding after birth, also known as postpartum haemorrhage (PPH),2 which leads to approximately 70,000 deaths per year.1 Although most deaths are preventable, PPH is the leading direct cause of maternal death worldwide,1 99% of which occur in low- and lower-middle income countries.2

Carbetocin Ferring is the first medicine approved under the new Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products (MAGHP). The MAGHP procedure builds on the existing Swissmedic procedure for Marketing Authorisation and makes it accessible to representatives of regulatory authorities in low- and middle-income countries. The procedure’s objective is to make essential medicines, like Carbetocin Ferring, available faster for patients in low- and middle-income countries.4

“As the COVID-19 pandemic impacts healthcare systems, communities and families all over the world, protecting maternal health has never been so critical. This milestone approval marks the first step towards ensuring that this innovative medicine reaches the women who need it – and reducing the thousands of preventable deaths from PPH every year, said Per Falk, President and Chief Science Officer at Ferring Pharmaceuticals. It is thanks to the collaboration with the World Health Organization and MSD for Mothers that we can mark this milestone and work towards development goals in global health.”

This landmark approval in Switzerland paves the way as Ferring now seeks registrations for Carbetocin Ferring for the prevention of PPH following all births, in low- and lower-middle income countries, where the burden of maternal mortality is greatest.2 Ferring is initially working with governments and partners in India, Kenya and Nigeria to secure the approval and introduction of Carbetocin Ferring, so that patients who need it can access it as soon as possible.

“This regulatory milestone is testament to the potential that public-private partnerships hold to address public health challenges, said Dr Julie L. Gerberding, Chief Patient Officer at MSD. Our ultimate goal through MSD for Mothers is to help create a world where no woman has to die while giving life. Today’s announcement brings us one step closer to realising this vision by improving the response to prevent PPH.”

Carbetocin Ferring ampoules will be made available by Ferring at an affordable and sustainable price* to publicly controlled or publicly funded healthcare facilities and healthcare facilities operating on a not-for-profit basis, including through social marketing, in low- and lower-middle income countries. Ferring will supply Carbetocin Ferring from state-of-the-art manufacturing sites that have passed Good Practice Manufacturing inspections by stringent regulatory authorities.7

“The loss of any woman during childbirth is a tragedy. Yet so many of the deaths caused by postpartum haemorrhage can be prevented, said Dr. Yeshita V Pujar, Consultant gynaecologist-obstetrician, KLES Prabhakar Kore Hospital & Medical Research Centre, Karnataka, India. This heat-stable formulation of carbetocin will play an important role in PPH prevention in countries which carry the greatest burden of maternal mortality, especially low- and lower-middle income countries. Many of these are in hotter parts of the world where cold-chain storage remains difficult to achieve and maintain. A heat-stable alternative for the prevention of PPH will be critical in saving maternal lives in settings where other effective uterotonics are unavailable or their quality cannot be guaranteed.”

Heat-stable carbetocin is included on the World Health Organization (WHO) Model List of Essential Medicines (EML),8 and in the WHO recommendations on uterotonics for the prevention of postpartum haemorrhage. The EML identifies medicines essential for addressing the most important public health needs globally.7 The guidelines recommend heat-stable carbetocin for the prevention of PPH in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics.**6

About the CHAMPION trial9
CHAMPION (Carbetocin Haemorrhage Prevention), the largest clinical trial in the prevention of PPH,*** was a double-blind, randomised, non-inferiority trial designed to compare the effectiveness and safety of investigational heat-stable carbetocin to oxytocin in the prevention of PPH after vaginal birth. The trial was funded by MSD for Mothers.**** Heat-stable carbetocin is a long-acting uterotonic developed by Ferring Pharmaceuticals.

* This price is a subsidised price of $0.31 +/- 10% per ampoule of 100 µg Carbetocin Ferring, Ex Works. This is comparable to the current United Nations Population Fund price for oxytocin of $0.32 per unit (10 I.U.).10
** The availability of Carbetocin Ferring is subject to regulatory review and approval in relevant countries.
*** Accurate as of trial closure in 2018
**** MSD for Mothers is an initiative of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build healthy families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

# # #

1 Say L, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014; 2(6):e323-e333. Available at: Last accessed: May 2020
2 WHO. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: Last accessed: May 2020
3 Swissmedic. First MAGHP approval in Switzerland. Available at: Last accessed: May 2020
4 Swissmedic. Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products (MAGHP). Available at: Last accessed: May 2020
5 World Bank. World Bank Country and Lending Groups. Published 2019. Available at: Last accessed: May 2020
6 WHO. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Available at: Last accessed: May 2020
7 Data on file
8 WHO Model List of Essential Medicines. Available at: Last accessed: May 2020
9 Widmer M, et al. Heat stable carbetocin vs oxytocin to prevent hemorrhage after vaginal birth. New England Journal of Medicine 2018;379:743-752
10 UNFPA Procurement Services. Oxytocin 10 I.U./ml injection in 1ml ampoule. Last accessed: May 2020

Contact information

For more information, please contact

Bhavin Vaid
Head of Corporate Communications
+41 79 191 0632 (mobile)

Lindsey Rodger
Senior Manager, Corporate Communications
+41 79 191 0486 (mobile)

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Eaton’s Twin Vortices Series Helps Hydrogen Fuel Cell Modules Operate at Peak Efficiency22.9.2020 12:30:00 CESTPress release

Power management company Eaton today announced its Twin Vortices Series (TVS®) technology has proven to be an integral component in hydrogen fuel cell modules, which benefit from the precise air flow control offered by the TVS unit to operate at peak efficiency. The TVS fuel cell blower is electrically driven, providing accurate and fast air control to enable rapid fuel cell voltage control for transient duty cycles. This press release features multimedia. View the full release here: Eaton’s Twin Vortices Series (TVS®) technology provides accurate and fast air control to enable rapid fuel cell voltage control. (Photo: Business Wire) Eaton’s TVS technology is known throughout the transportation industry for its supercharged internal combustion engine applications, but minor modifications have made the unit ideal for fuel cells. To operate efficiently, fuel cell stacks need precisely controlled air and hydrogen flow. Fuel cells ar

Seoul Semiconductor’s WICOP Bi-color LEDs Are Shining in the Headlamp of Audi A4 Model Year 202022.9.2020 11:11:00 CESTPress release

Seoul Semiconductor Co., Ltd. (“Seoul”) (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that it has supplied WICOP Bi-color (2 colors in one package) LED products for the daytime running lights and front turn signals of the 2020 Audi A4 (B9 facelift) headlamp. This press release features multimedia. View the full release here: 2020 Audi A4 with Seoul Semiconductor’s WICOP Bi-Color LEDs (Source: Audi) This is the first example of Seoul Semiconductor's WICOP product being mounted on an Audi headlamp. WICOP Bi-color LED is a core patented technology of Seoul Semiconductor that realizes both white and yellow in one package. It is designed to directly mount the LED chip on the board without an additional package. “Due to the narrow space between the light emitting surfaces of the Bi-color LED, it is technically beneficial to light up one cavity with yellow for turn and white for DRL. This advanta

Medis Selects Veeva CRM to Deliver Personalized Experiences to Healthcare Professionals22.9.2020 10:00:00 CESTPress release

Veeva Systems (NYSE:VEEV) today announced that Medis has switched to multichannel Veeva CRM in 15 countries across Central and Eastern Europe to advance its commercial strategy and drive more efficient and effective interactions with healthcare professionals (HCPs). “Veeva CRM gives our teams a flexible solution that adapts to the unique go to market strategies of every customer,” said Kristina Jerič, multichannel implementation lead at Medis. “Now, our field teams can get the customer insights they need to quickly drive targeted, relevant interactions with HCPs.” Medis is a leading independent medical marketing company that specializes in the commercialization of innovative pharmaceutical products. The company needed a CRM solution to effectively execute their customers’ commercial and medical strategies with speed and compliance. With Veeva CRM, Medis can now efficiently deliver compliant, tailored experiences to HCPs across all channels, including face-to-face, email, and web. “Veev

Veeva Commercial Cloud Selected by Idorsia to Accelerate Digital Engagement Globally22.9.2020 10:00:00 CESTPress release

Veeva Systems(NYSE: VEEV) today announced that Idorsia Pharmaceuticals Ltd (SIX: IDIA) has selected Veeva Commercial Cloud to enable its digital field force in the U.S., Japan, and countries across Europe. Idorsia is at the forefront of innovative therapies and needed best-in-class cloud technology to drive its global commercial strategy. Veeva Commercial Cloud brings together multichannel engagement, data, content, and analytics to give Idorsia the foundation for digital excellence. “Veeva is an important partner that has helped us to rapidly scale-up, supporting our growth plans,” said Joseph Bejjani, CIO at Idorsia. “Veeva Commercial Cloud streamlines commercial processes from pre-launch planning to execution and digitally enables our field force to more effectively engage customers.” Adoption of Veeva Commercial Cloud builds upon Idorsia’s success with Veeva Development Cloud in speeding end-to-end product development. Idorsia is a fast-growing biopharmaceutical company based in Sw

CGTN: China Makes Proposals for UN's Role in Post-Pandemic Era22.9.2020 08:48:00 CESTPress release

The United Nations, beginning with 51 signatories at the end of World War II, has now grown to be a 193-nation body. As it celebrates its 75th founding anniversary, the organization and multilateralism it represents are facing unprecedented challenges with the rise of unilateralism and protectionism. This press release features multimedia. View the full release here: The challenges are being compounded by COVID-19, which has infected more than 31 million people and taken over 960,000 lives worldwide. "What kind of UN does the world need and what role should it play in the post-pandemic era?" Chinese President Xi Jinping raised the question and made proposals on Monday when addressing the high-level meeting to commemorate the 75th anniversary of the UN via video link. The UN should uphold justice as countries, regardless of their sizes, are equal and should respect each other, Xi said, noting that this is a requirement of the pro

inwi money Launches International Money Transfer Capability in Partnership With WorldRemit and MFS Africa22.9.2020 08:00:00 CESTPress release

inwi money, a subsidiary of inwi and leading telecom player in mobile money services, has expanded its offering with the launch of an international money transfer service for its “inwi money” customers. “The launch of this new service is a concrete result of our efforts to diversify the available payment methods in Morocco, to widen financial inclusion to encompass a greater number of Moroccans and to reduce dependency on cash transactions. inwi customers can now receive money from their loved ones abroad quickly and securely”, explains Nicolas Levi, CEO of inwi money. How does it work? Once the money transfer is authorised by the sender via the WorldRemit platform, the recipient is notified by SMS, and the transferred amount is directly credited to their inwi money account. This new service is the result of a strategic partnership between inwi money and WorldRemit, a leading provider of online money transfer services, as well as MFS Africa, a leading Pan-African fintech which operates

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom